High Dose Rate Interstitial Brachytherapy in Soft Tissue Sarcomas: Technical Aspect.
- Author:
Mison CHUN
1
;
Seunghee KANG
;
Byoung Suck KIM
;
Young Taek OH
Author Information
1. Department of Radiation Oncology, School of Medicine, Ajou University, Suwon, Korea.
- Publication Type:Original Article
- Keywords:
Interstitial brachytherapy;
High dose rate;
Soft tissue sarcoma;
Technical aspect
- MeSH:
Axis, Cervical Vertebra;
Brachytherapy*;
Catheters;
Diagnosis;
Fibrosis;
Follow-Up Studies;
Hemorrhage;
Humans;
Radiotherapy;
Recurrence;
Sarcoma*;
Tissue Expansion Devices
- From:The Journal of the Korean Society for Therapeutic Radiology and Oncology
1999;17(1):43-51
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To discuss the technical aspect of interstitial brachytherapy including method of implant, insertion time of radioactive source, total radiation dose, and complication, we reviewed patients who had diagnoses of soft tissue sarcoma and were treated by conservative surgery, interstitial implant and external beam radiation therapy. MATERIALS AND METHODS: Between May 1995 and Dec. 1997, ten patients with primary or recurrent soft tissue sarcoma underwent surgical resection (wide margin excision) and received radiotherapy including interstitial brachytherapy. Catheters were placed with regular intervals of 1~1.5 cm immediately after tumor removal and covering the critical structures, such as neurovascular bundle or bone, with gelform, muscle, or tissue expander in the cases where the tumors were close to those structures. Brachytherapy consisted of high dose rate, iridium-192 implant which delivered 12~15 Gy to 1 cm distance from the center of source axis with 2~2.5 Gy/fraction, twice a day, starting on 6th day after the surgery. Within one month after the surgery, total dose of 50~55 Gy was delivered to the tumor bed with wide margin by the external beam radiotherapy. RESULTS: All patients completed planned interstitial brachytherapy without acute side effects directly related with catheter implantation such as infection or bleeding. With median follow up duration of 25 months (range 12~41 months), no local recurrences were observed. And there was no severe form of chronic complication (RTOG/EORTC grade 3 or 4). CONCLUSION: The high dose rate interstitial brachytherapy is easy and safe way to minimize the radiation dose delivered to the adjacent normal tissue and to decrease radiation induced chronic morbidity such as fibrosis by reducing the total dose of external radiotherapy in the management of soft tissue sarcoma with conservative surgery.
